Список литературы
1. Отраслевой стандарт ОСТ 91500.11.0007-2003 Система стандартизации в здравоохранении Российской Федерации "Протокол ведения больных. профилактика тромбоэмболии легочной артерии при хирургических и иных инвазивных вмешательствах" (утв. приказом Минздрава РФ от 9 июня 2003 г. N 233).
2. Российский Консенсус «Профилактика послеоперационных венозных тромбоэмболических осложнений». -М., 2000.
3. Тихилов Р. М., Стойко Ю. М., Замятин М. Н., Божкова С. А. Профилактика тромбоэмболических осложнений в травматологии и ортопедии. Методические рекомендации под редакцией академика РАМН Ю. Л. Шевченко. М.2006. С. 20.
4. Adolf J. Fritsche HM. Haas S. Hennig FF, Horbach T. Kastl S. Koppenhagen K, Michaelis HC. Rhamanzadeh R. Summa W. Wagner W. Weber U. Wolf H. Comparison of 3.000 IU aXa of the low molecular weight heparin certoparin with 5,000 IU aXa in prevention of deep vein thrombosis after total hip replacement. German Thrombosis Study Group. Int Angiol. 1999:18:122-6.
5. American Academy of Orthopaedic Surgeons. American Academy of Orthopaedic Surgeons clinical guideline on prevention of pulmonary embolism in patients undergoing total hip or knee arthroplasty. 2007 May. [
Ссылки доступны только зарегистрированным пользователям ]. Accessed 2008 Oct 20.
6. Amin AK. Patton JT. Cook RE. Brenkel IJ. Does obesity influence the clinical outcome at five years following total knee replacement for osteoarthritis? J Bone Joint Surg Br. 2006:88:335-40.
7. Anders MJ, Lifeso RM, Landis M, Mikulsky J. Meinking C, McCracken KS. Effect of preoperative donation of autologous blood on deep-vein thrombosis following total joint arthroplasty of the hip or knee. J Bone Joint Surg Am. 1996:78:574-80.
8. Arbit E. Goldberg M. Gomez-Orellana I. Majuru S. Oral heparin: status review. Thromb J. 2006:4:6.
9. Bae H. Westrich GH. Sculco TP. Salvati EA. Reich LM. The effect of preoperative donation of autologous blood on deep-vein thrombosis after total hip arthroplasty. J Bone Joint Surg Br. 2001:83:676-9.
10. Balk EM. Bonis PA. Moskowitz H. Schmid CH. loannidis JP, Wang C, Lau J. Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials. JAMA. 2002:287:2973-82.
11. Bauer KA. Eriksson Bl. Lassen MR. Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med. 2001:345:1305-10.
12. Bern M. Deshmukh RV. Nelson R. Bierbaum B. Sevier N, Howie N, Losina E, Katz JN. Low-dose warfarin coupled with lower leg compression is effective prophylaxis against thromboembolic disease after hip arthroplasty. J Arthroplasty. 2007:22:644-50.
13. Boscainos PJ. McLardy-Smith P. Jinnah RH. Deep vein thrombosis prophylaxis after total-knee arthroplasty. Curr Opin Orthop. 2006:17:60-7.
14. Bozic KJ. Auerbach A. Maselli J. Smith A. Vail TP. Is there a role for aspirin in venous thromboembolism prophylaxis after total knee arthroplasty? Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons; 2007 Nov 2-4; Dallas, TX. James A. Rand Award Paper.
15. Bratzler DW. Hunt DR. The surgical infection prevention and surgical care improvement projects: national initiatives to improve outcomes for patients having surgery. Clin Infect Dis. 2006:43:322-30.
16. Burnett RS. Clohisy JC. Wright RW. McDonald DJ. Shively RA. Givens SA. Barrack RL. Failure of the American College of Chest Physicians-IA protocol for Lovenox in clinical outcomes for thromboembolic prophylaxis. J Arthroplasty. 2007:22:317-24.
17. Callaghan JJ. Dorr LD. Engh GA. Hanssen AD. Healy WL. Lachiewicz PF. Lonner JH. Lotke PA, Ranawat CS. Ritter MA. Salvati EA. Sculco TP. Thornhill TS; American College of Chest Physicians. Prophylaxis for thromboembolic disease: recommendations from the American College of Chest Physicians—are they appropriate for orthopaedic surgery? J Arthroplasty. 2005:20:273-4.
18. Callaghan JJ. Warth LC. Hoballah J, Liu S. Wells C. Low-morbidity low-cost deep vein thrombosis prophylaxis in low-risk patients undergoing total knee arthroplasty. Presented at the Annual Meeting of the American Association of Hip and Knee Surgeons; 2007 Nov 2-4; Dallas. TX. Paper no. 23.
19. Caprini JA. Arcelus Jl. Motykie G. Kudrna JC. Mokhtee D, Reyna JJ. The influence of oral anticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vase Surg. 1999:30:813-20.
20. Cohen AT. Hirst C. Sherrill B. Holmes P. Fidan D. Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgery. Br J Surg. 2005:92:1335-44.
21. Colweil CW Jr. Berkowitz SD. Davidson BL. Lotke PA, Ginsberg JS, Lieberman JR. Neubauer J, McElhattan JL, Peters GR, Francis CW. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003;1:2119-30.
22. Colweil CW Jr. Kwong LM. Turpie AG. Davidson BL. Flexibility in administration of fondaparinux for prevention of symptomatic venous thromboembolism in orthopaedic surgery. J Arthroplasty. 2006:21:36-45.
23. Colwell CVV Jr. Berkowitz SD. Lieberman JR. Comp PC. Ginsberg JS. Paiement G. McElhattan J. Roth AW. Francis CW; EXULT B Study Group. Oral direct thrombin inhibitor ximelagatran compared with warfarin for the prevention of venous thromboembolism after total knee arthroplasty. J Bone Joint Surg Am. 2005;87:2169-77.
24. Colwell CVV Jr. Collis DK. Paulson R. McCutchen JW. Bigler GT. Lutz S. Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am. 1999:81: 932-40.
25. Dalldorf PG. Perkins FM. Totterman S. Pellegrini VD Jr. Deep venous thrombosis following total hip arthroplasty. Effects of prolonged postoperative epidural anesthesia. J Arthroplasty. 1994;9:611-6.
26. Dentali F, Ageno W, Imberti D. Retrievable vena cava filters: clinical experience. Curr Opin Pulm Med. 2006:12:304-9.
27. DiGiovanni CW. Restrepo A. Gonzalez Delia Valle AG. Sharrock NE. McCabe JP. Sculco TP. Pellicci PM. Salvati EA. The safety and efficacy of intraoperative heparin in total hip arthroplasty. Clin Orthop Relat Res. 2000:379:178-85.
28. Eriksson Bl. Bergqvist D. Kalebo P. Dahl OE. Lindbratt S. Bylock A. Frison L. Eriksson UG. Welin L. Gustafsson D; Melagatran for Thrombin inhibition in Orthopaedic surgery. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002:360:1441-7.
29. Eriksson Bl. Borris L. Dahl OE. Haas S. Huisman MV. Kakkar AK. Misselwitz F. Kalebo P; ODlXa-HIP Study Investigators. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121-8.
30. Eriksson Bl. Dahl OE. Buller HR. Hettiarachchi R. Rosencher N. Bravo ML. Ahnfelt L. Piovella F. Stangier J. Kalebo P. Reilly P; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005:3:103-11.